Source
Patsnap
The ATTR amyloidosis pipeline has expanded far beyond patisiran, with RNA interference, CRISPR gene editing, monoclonal antibodies, and next-generation stabilizers all now represented in the patent record — and new entrants from Amgen and Chinese biotech intensifying the competitive landscape in 2025.
News Url